• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
GTG
Click for more information
0.00% 3.9¢

GENETIC TECHNOLOGIES LIMITED - Announcements

Market Cap $5.671M  ! watchlist Created with Sketch. Add to my watchlist

Genetic Technologies Limited is an Australia-based diversified molecular diagnostics... Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and morMore

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
GTGSettlement with Reproductive Genetics InstitutePRICE SENSITIVE28/06/13
GTGIndependent study supports utilization of BREVAGen24/06/13
GTGSettlement with BioscientiaPRICE SENSITIVE24/06/13
GTGExecution of seventh PPO agreementPRICE SENSITIVE19/06/13
GTGUS gene patenting update17/06/13
GTGExpiry of options03/06/13
GTGGTG executes sixth PPO agreementPRICE SENSITIVE20/05/13
GTGSettlement Agreement executed with LabCorpPRICE SENSITIVE06/05/13
GTGGTG executes fifth PPO agreementPRICE SENSITIVE03/05/13
GTGASX Appendix 4C and quarterly activities reportPRICE SENSITIVE30/04/13
GTGSettlement with Genetics & IVF Institute Inc.PRICE SENSITIVE30/04/13
GTGGTG executes agreement with PreventionGeneticsPRICE SENSITIVE29/04/13
GTGFurther re-examination of US patent19/04/13
GTGReply to QueryPRICE SENSITIVE17/04/13
GTGAppendix 3B26/03/13
GTGExpiry of options26/03/13
GTGLicensing update - March 2013PRICE SENSITIVE19/03/13
GTGUS patent re-examination updatePRICE SENSITIVE15/03/13
GTGAmended ASX Appendix 4D - 31 December 201226/02/13
GTGHalf-Year results and ASX Appendix 4DPRICE SENSITIVE22/02/13
GTGAppendix 3B06/02/13
GTGAppendix 3B and cleansing notice25/01/13
GTGAppendix 4C - quarterlyPRICE SENSITIVE25/01/13
GTGPresentation at US conference07/01/13
GTGLicensing update - December 2012PRICE SENSITIVE20/12/12
GTGAppointment of permanent CEO and Non-Executive DirectorPRICE SENSITIVE10/12/12
GTGGTG resolves infringement claim against 454 Life SciencesPRICE SENSITIVE06/12/12
GTGASX Appendix 3Z - Mel Bridges30/11/12
GTGASX Appendix 3Z - Huw Jones29/11/12
GTGASX Appendix 3Z - Greg Brown29/11/12
GTGImmunAid Annual General Meeting28/11/12
GTGAppointment of Chairman and Acting CEOPRICE SENSITIVE28/11/12
GTGResignationsPRICE SENSITIVE27/11/12
GTGResults from 2012 Annual General Meeting27/11/12
GTG2012 AGM materials27/11/12
GTGAppendix 3B29/10/12
GTGExpiry of options26/10/12
GTGAppendix 4C - quarterlyPRICE SENSITIVE25/10/12
GTGUS Annual Report on Form 20-F - 30 June 201225/10/12
GTGIssue of shares, cleansing notice and Appendix 3B19/10/12
GTG2012 Notice of AGM, Proxy and Annual Report18/10/12
GTGGenetic Technologies executes agreement with One Lambda Inc.18/10/12
GTGGenetic Technologies files four new infringement suitsPRICE SENSITIVE15/10/12
GTGBREVAGen cleared for sale in FloridaPRICE SENSITIVE25/09/12
GTGKey US managerial appointment13/09/12
GTGGTG executes license with Conexio GenomicsPRICE SENSITIVE06/09/12
GTGGTG files suit against Reproductive Genetics InstitutePRICE SENSITIVE30/08/12
GTG2012 ASX Appendix 4E and audited Financial ReportPRICE SENSITIVE28/08/12
GTGGenetic Technologies receives CE mark approval for BREVAGenPRICE SENSITIVE08/08/12
GTGAppendix 4C - quarterlyPRICE SENSITIVE30/07/12
GTGBREVAGen cleared for sale in CaliforniaPRICE SENSITIVE26/07/12
GTGDirector Appointment/Resignation24/07/12
GTGNon-coding licensing updatePRICE SENSITIVE09/07/12
GTGAppendix 3B30/05/12
GTGBREVAGen credentialing updatePRICE SENSITIVE22/05/12
GTGSettlement with GeneSeekPRICE SENSITIVE09/05/12
GTGAppendix 4C - quarterlyPRICE SENSITIVE24/04/12
GTGAppendix 3B20/04/12
GTGForfeiture of options19/04/12
GTGImmunAid Pty. Ltd. secures cornerstone fundingPRICE SENSITIVE13/04/12
GTGChange of Director's Interest Notice11/04/12
GTGChange in substantial holding11/04/12
GTGChange of Director's Interest Notice02/03/12
GTGUpdate on US and Australian gene patenting litigationPRICE SENSITIVE29/02/12
GTGHalf-Year results - 31 December 201127/02/12
GTGHalf Yearly Report and AccountsPRICE SENSITIVE27/02/12
GTG +Conclusion of second patent infringement suitPRICE SENSITIVE21/02/12
GTGGTG receives CLIA Certificate of CompliancePRICE SENSITIVE16/02/12
GTGForfeiture of options06/02/12
GTGSettlement with Eurofins STAPRICE SENSITIVE06/02/12
GTGIn memoriam Dr. Malcolm Simons02/02/12
GTGAppendix 4C - quarterlyPRICE SENSITIVE30/01/12
GTGResponse to ASX Price and Volume QueryPRICE SENSITIVE27/01/12
GTGAppendix 3B25/01/12
GTGGTG appoints Dr Mel Bridges as Chairman16/12/11
GTGLadenburg Thalmann Initiates Research Coverage01/12/11
GTGSettlement and License Agreement with AutoImmun DiagnostikaPRICE SENSITIVE01/12/11
GTGUS Annual Report on Form 20-F - 30 June 201122/11/11
GTGResults from 2011 Annual General Meeting21/11/11
GTGMaterials for 2011 Annual General Meeting21/11/11
GTGImmunAid press releasePRICE SENSITIVE02/11/11
GTGAppendix 4C - quarterlyPRICE SENSITIVE26/10/11
GTGForfeiture of options24/10/11
GTGExecution of Settlement and License Agreement with Hologic19/10/11
GTGPresentation at AusBiotech 2011 National Conference19/10/11
GTGBREVAGen changing the way US physicians assess breast cancer18/10/11
GTGAnnual Report to shareholders14/10/11
GTGNotice of Annual General Meeting/Proxy Form12/10/11
GTGAppendix 3B03/10/11
GTGDirector Appointment/Resignation03/10/11
GTGInvestor presentation at Rodman and Renshaw13/09/11
GTGGTG maiden full year profit25/08/11
GTGPreliminary Final ReportPRICE SENSITIVE25/08/11
GTGSettlement with Attomol GmbHPRICE SENSITIVE25/08/11
GTGAppendix 4C - quarterlyPRICE SENSITIVE29/07/11
GTGCleansing notice27/07/11
GTGAppendix 3B27/07/11
GTGReinstatement to Official QuotationPRICE SENSITIVE22/07/11
GTGCompletion of Successful Capital raisingPRICE SENSITIVE22/07/11
GTGResponse to ASX Price QueryPRICE SENSITIVE22/07/11
GTGSettlement with Reproductive Genetics Institute
28/06/13PRICE SENSITIVE
GTGIndependent study supports utilization of BREVAGen
24/06/13
GTGSettlement with Bioscientia
24/06/13PRICE SENSITIVE
GTGExecution of seventh PPO agreement
19/06/13PRICE SENSITIVE
GTGUS gene patenting update
17/06/13
GTGExpiry of options
03/06/13
GTGGTG executes sixth PPO agreement
20/05/13PRICE SENSITIVE
GTGSettlement Agreement executed with LabCorp
06/05/13PRICE SENSITIVE
GTGGTG executes fifth PPO agreement
03/05/13PRICE SENSITIVE
GTGASX Appendix 4C and quarterly activities report
30/04/13PRICE SENSITIVE
GTGSettlement with Genetics & IVF Institute Inc.
30/04/13PRICE SENSITIVE
GTGGTG executes agreement with PreventionGenetics
29/04/13PRICE SENSITIVE
GTGFurther re-examination of US patent
19/04/13
GTGReply to Query
17/04/13PRICE SENSITIVE
GTGAppendix 3B
26/03/13
GTGExpiry of options
26/03/13
GTGLicensing update - March 2013
19/03/13PRICE SENSITIVE
GTGUS patent re-examination update
15/03/13PRICE SENSITIVE
GTGAmended ASX Appendix 4D - 31 December 2012
26/02/13
GTGHalf-Year results and ASX Appendix 4D
22/02/13PRICE SENSITIVE
GTGAppendix 3B
06/02/13
GTGAppendix 3B and cleansing notice
25/01/13
GTGAppendix 4C - quarterly
25/01/13PRICE SENSITIVE
GTGPresentation at US conference
07/01/13
GTGLicensing update - December 2012
20/12/12PRICE SENSITIVE
GTGAppointment of permanent CEO and Non-Executive Director
10/12/12PRICE SENSITIVE
GTGGTG resolves infringement claim against 454 Life Sciences
06/12/12PRICE SENSITIVE
GTGASX Appendix 3Z - Mel Bridges
30/11/12
GTGASX Appendix 3Z - Huw Jones
29/11/12
GTGASX Appendix 3Z - Greg Brown
29/11/12
GTGImmunAid Annual General Meeting
28/11/12
GTGAppointment of Chairman and Acting CEO
28/11/12PRICE SENSITIVE
GTGResignations
27/11/12PRICE SENSITIVE
GTGResults from 2012 Annual General Meeting
27/11/12
GTG2012 AGM materials
27/11/12
GTGAppendix 3B
29/10/12
GTGExpiry of options
26/10/12
GTGAppendix 4C - quarterly
25/10/12PRICE SENSITIVE
GTGUS Annual Report on Form 20-F - 30 June 2012
25/10/12
GTGIssue of shares, cleansing notice and Appendix 3B
19/10/12
GTG2012 Notice of AGM, Proxy and Annual Report
18/10/12
GTGGenetic Technologies executes agreement with One Lambda Inc.
18/10/12
GTGGenetic Technologies files four new infringement suits
15/10/12PRICE SENSITIVE
GTGBREVAGen cleared for sale in Florida
25/09/12PRICE SENSITIVE
GTGKey US managerial appointment
13/09/12
GTGGTG executes license with Conexio Genomics
06/09/12PRICE SENSITIVE
GTGGTG files suit against Reproductive Genetics Institute
30/08/12PRICE SENSITIVE
GTG2012 ASX Appendix 4E and audited Financial Report
28/08/12PRICE SENSITIVE
GTGGenetic Technologies receives CE mark approval for BREVAGen
08/08/12PRICE SENSITIVE
GTGAppendix 4C - quarterly
30/07/12PRICE SENSITIVE
GTGBREVAGen cleared for sale in California
26/07/12PRICE SENSITIVE
GTGDirector Appointment/Resignation
24/07/12
GTGNon-coding licensing update
09/07/12PRICE SENSITIVE
GTGAppendix 3B
30/05/12
GTGBREVAGen credentialing update
22/05/12PRICE SENSITIVE
GTGSettlement with GeneSeek
09/05/12PRICE SENSITIVE
GTGAppendix 4C - quarterly
24/04/12PRICE SENSITIVE
GTGAppendix 3B
20/04/12
GTGForfeiture of options
19/04/12
GTGImmunAid Pty. Ltd. secures cornerstone funding
13/04/12PRICE SENSITIVE
GTGChange of Director's Interest Notice
11/04/12
GTGChange in substantial holding
11/04/12
GTGChange of Director's Interest Notice
02/03/12
GTGUpdate on US and Australian gene patenting litigation
29/02/12PRICE SENSITIVE
GTGHalf-Year results - 31 December 2011
27/02/12
GTGHalf Yearly Report and Accounts
27/02/12PRICE SENSITIVE
GTG +Conclusion of second patent infringement suit
21/02/12PRICE SENSITIVE
GTGGTG receives CLIA Certificate of Compliance
16/02/12PRICE SENSITIVE
GTGForfeiture of options
06/02/12
GTGSettlement with Eurofins STA
06/02/12PRICE SENSITIVE
GTGIn memoriam Dr. Malcolm Simons
02/02/12
GTGAppendix 4C - quarterly
30/01/12PRICE SENSITIVE
GTGResponse to ASX Price and Volume Query
27/01/12PRICE SENSITIVE
GTGAppendix 3B
25/01/12
GTGGTG appoints Dr Mel Bridges as Chairman
16/12/11
GTGLadenburg Thalmann Initiates Research Coverage
01/12/11
GTGSettlement and License Agreement with AutoImmun Diagnostika
01/12/11PRICE SENSITIVE
GTGUS Annual Report on Form 20-F - 30 June 2011
22/11/11
GTGResults from 2011 Annual General Meeting
21/11/11
GTGMaterials for 2011 Annual General Meeting
21/11/11
GTGImmunAid press release
02/11/11PRICE SENSITIVE
GTGAppendix 4C - quarterly
26/10/11PRICE SENSITIVE
GTGForfeiture of options
24/10/11
GTGExecution of Settlement and License Agreement with Hologic
19/10/11
GTGPresentation at AusBiotech 2011 National Conference
19/10/11
GTGBREVAGen changing the way US physicians assess breast cancer
18/10/11
GTGAnnual Report to shareholders
14/10/11
GTGNotice of Annual General Meeting/Proxy Form
12/10/11
GTGAppendix 3B
03/10/11
GTGDirector Appointment/Resignation
03/10/11
GTGInvestor presentation at Rodman and Renshaw
13/09/11
GTGGTG maiden full year profit
25/08/11
GTGPreliminary Final Report
25/08/11PRICE SENSITIVE
GTGSettlement with Attomol GmbH
25/08/11PRICE SENSITIVE
GTGAppendix 4C - quarterly
29/07/11PRICE SENSITIVE
GTGCleansing notice
27/07/11
GTGAppendix 3B
27/07/11
GTGReinstatement to Official Quotation
22/07/11PRICE SENSITIVE
GTGCompletion of Successful Capital raising
22/07/11PRICE SENSITIVE
GTGResponse to ASX Price Query
22/07/11PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
3.9¢ 		Change
0.000(0.00%) 		Mkt cap ! $5.671M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0
GTG (ASX) Chart

Top Stories

US election outcomes: Key economic and market takeaways

This week on Money @ Investing, Mitch Olarenshaw and I break down the recent U.S. presidential election, focusing on its effects on the stock market and the broader economic outlook. Here’s what we covered:1. Election results and policy insightsThe Republican Party&CloseCurlyQuote...
Power gets set for 1000-metre maiden drilling program in Brazil Power Minerals Ltd is planning a maiden drilling program to 1000 metres to test targets at its Nióbio project in Brazil
Quit before you're fired: Russia bans uranium exports to USA, duplicating extant US ban Russia's ban of uranium exports to the USA came days before Biden allowed Ukraine use long-range missiles.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.